ASC Therapy / Rigshospitalet - LARVOL DELTA

Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase 2 Randomised, Placebo-Controlled Trial. (PubMed, Clin Cancer Res) - "We could not confirm superiority of the ASC relative to placebo. ASC therapy significantly improved UWS in previous head and neck cancer patients, whereas placebo resulted in an insignificant increase."

Journal • P2 data • Stroma • Dental Disorders • Head and Neck Cancer • Oncology • Solid Tumor • Xerostomia

Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction - The SCIENCE Trial. (PubMed, Eur J Heart Fail) - "The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the predefined endpoints and induce restoration of cardiac function or clinical symptoms."

Journal • Review • Stroma • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Long-Term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase 1/2 Randomized Trial. (PubMed, Clin Cancer Res) - "Our data show that ASC therapy is safe with a clinically relevant effect on xerostomia-related symptoms. Confirmation in larger randomized controlled trials is warranted."

Journal • P1/2 data • Dental Disorders • Oncology • Oropharyngeal Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Xerostomia

ASC COVID-19: ASC Therapy for Patients With Severe Respiratory COVID-19 (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Rigshospitalet, Denmark; N=40 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CRP

ASC COVID-19: ASC Therapy for Patients With Severe Respiratory COVID-19 (clinicaltrials.gov) - P1/2; N=40; Not yet recruiting; Sponsor: Rigshospitalet, Denmark

Clinical • New P1/2 trial